Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

Journal for ImmunoTherapy of Cancer

Volumn 6, Issue 1, 2018, Pages

  Kaufman, Howard L ^a,b   Russell, Jeffery S ^c,d   Hamid, Omid ^e   Bhatia, Shailender ^f   Terheyden, Patrick ^g   D'Angelo, Sandra P ^h   Shih, Kent C ⁱ   Lebbé, Céleste ^j   Milella, Michele ^k   Brownell, Isaac ^l   Lewis, Karl D ^m   Lorch, Jochen H ⁿ   von Heydebreck, Anja ^o   Hennessy, Meliessa ^p   Nghiem, Paul ^f  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b Replimune Ltd   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d Immunocore Limited   (United Kingdom)

^e Angeles Clinic and Research Institute   (United States)

^f UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^g UNIVERSITY OF LÜBECK   (Germany)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ SARAH CANNON RESEARCH INSTITUTE   (United States)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^l NATIONAL CANCER INSTITUTE   (United States)

^m UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁿ DANA FARBER CANCER INSTITUTE   (United States)

^o MERCK KGAA   (Germany)

^p EMD SERONO INC   (United States)

more..

Author keywords

Avelumab; Javelin; Merkel cell carcinoma; Pd L1

Indexed keywords

AVELUMAB; PROGRAMMED DEATH 1 LIGAND 1; MONOCLONAL ANTIBODY;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; DISEASE EXACERBATION; DRUG EFFICACY; ELECTROCORTICOGRAPHY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LIFE EXPECTANCY; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MERKEL CELL CARCINOMA; MERKEL CELL POLYOMAVIRUS; METASTASIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; CLINICAL TRIAL; MIDDLE AGED; PATHOLOGY; SKIN TUMOR; TIME FACTOR;

AGED; ANTIBODIES, MONOCLONAL; CARCINOMA, MERKEL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SKIN NEOPLASMS; TIME FACTORS;

EID: 85040729219     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-017-0310-x     Document Type: Article

References (16)

1. Lebbe C, Becker JC, Grob JJ, Malvehy J, Del Marmol V, Pehamberger H, et al. Diagnosis and treatment of Merkel cell carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51(16):2396-403.
2. Terheyden P, Becker JC. New developments in the biology and the treatment of metastatic Merkel cell carcinoma. Curr Opin Oncol. 2017; March 9. [Epub ahead of print]
3. Schadendorf D, Lebbe C, Zur Hausen A, Avril MF, Hariharan S, Bharmal M, et al. Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer. 2017;71:53-69.
4. Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol. 2005;23(10):2300-9.
5. NCCN Clinical practice guidelines in oncology: Merkel cell carcinoma. Version I.2018.
6. Nghiem P, Kaufman HL, Bharmal M, Mahnke L, Phatak H, Becker JC. Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncol. 2017;13(14):1263-79.
7. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced Merkel cell carcinoma. N Engl J Med. 2016;374(26):2542-52.
8. Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374-85.
9. Topalian SL, Bhatia S, Hollebecque A, Awada A, De Boer JP, Kudchadkar RR, et al. Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): efficacy and safety in Merkel cell carcinoma (MCC). Cancer Res 2017;77(Suppl 13 [Abstract CT074]). doi: https://doi.org/10.1158/1538-7445.AM2017-CT074.
10. Bavencio. (avelumab) injection [package insert]. Darmstadt: Merck KGaA; 2017.
11. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.
12. Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Durable responses to avelumab (anti-PD-L1) in patients with Merkel cell carcinoma progressed after chemotherapy: 1-year efficacy update. Cancer Res 2017;77(Suppl 13 [Abstract CT079]). doi: https://doi.org/10.1158/1538-7445.AM2017-CT074.
13. Cowey CL, Mahnke L, Espirito J, Helwig C, Oksen D, Bharmal M. Real-world outcomes of patients with metastatic Merkel cell caricnoma treated with chemotherapy in the USA. Future Oncol. 2017;13(19):1699-710.
14. Becker J, Lorenz E, Haas G, Helwig C, Oksen D, Mahnke L, et al. Evaluation of real world treatment outcomes in patients with metastatic Merkel cell carcinoma (MCC) following second line chemotherapy. Ann Oncol 2016;26(Suppl 3 [Abstract 2602]). doi: https://doi.org/10.1158/1538-7445.AM2017-CT074.
15. Iyer JG, Blom A, Doumani R, Lewis C, Tarabadkar ES, Anderson A, et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 2016;5(9):2294-301.
16. Schadendorf D, Nghiem P, Bhatia S, Hauschild A, Saiag P, Mahnke L, et al. Immune evasion mechanisms and immune checkpoint inhibition in advanced Merkel cell carcinoma. OncoImmunology. 2017; https://doi.org/10.1080/2162402X.2017.1338237.